SCHEMBL29699494

SCHEMBL29699494

c1nc2ccc(Oc3c[nH]nn3)cc2s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ HKDC1 Q2TB90 1/20 0.39
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ DYRK1A Q13627 3/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ PKM P14618 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ IKBKB O14920 2/20 0.35
▸ GHSR Q92847 3/20 0.34
▸ RIPK1 Q13546 1/20 0.34
▸ TGFBR1 P36897 2/20 0.33
▸ CSNK2A2 P19784 2/20 0.33
▸ CLK1 P49759 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8517411 0.73 IKBKB (0.55) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL18004134 0.72 NPC1 (0.49) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL21944747 0.72 TDP1 (0.45) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL23133 0.71 NPC1 (0.57) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL29699469 0.71 NPC1 (0.39) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL22608661 0.70 HAO1 (0.56) —
SCHEMBL29699383 0.70 IRAK4 (0.46) NPC1RAB9AMEN1KMT2AIKBKB
Bromide SCHEMBL1193036 0.69 NPC1 (0.56) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL18003523 0.69 NPC1 (0.52) NPC1RAB9AKDM4ETDP1L3MBTL1
SCHEMBL4160781 0.68 ALDH1A1 (0.60) NPC1RAB9AKDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT NPC1 1113/4885RAB9A 3978/4885KDM4E 3325/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback